Acorda Therapeutics (DB:CDG) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CDG Stock Overview

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. More details

CDG fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings have grown 10.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (€15M)

Shareholders have been diluted in the past year

Acorda Therapeutics, Inc. Competitors

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

Paion

XTRA:PA8

€2.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Price History & Performance

Summary of all time highs, changes and price drops for Acorda Therapeutics
Historical stock prices
Current Share Price	US$8.42
52 Week High	US$21.80
52 Week Low	US$5.64
Beta	1.43
11 Month Change	0%
3 Month Change	-6.83%
1 Year Change	10.25%
33 Year Change	-83.90%
5 Year Change	-99.70%
Change since IPO	-98.76%

Recent updates

Shareholder Returns

	CDG	DE Biotechs	DE Market
7D	0%	-0.7%	-0.02%
1Y	10.2%	-17.2%	8.2%

Return vs Industry: CDG exceeded the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: CDG exceeded the German Market which returned 5.9% over the past year.

Price Volatility

Is CDG's price volatile compared to industry and market?
CDG volatility
CDG Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: CDG's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine CDG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1995	111	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. Fundamentals Summary

How do Acorda Therapeutics's earnings and revenue compare to its market cap?
CDG fundamental statistics
Market cap	€14.12m
Earnings (TTM)	-€19.42m
Revenue (TTM)	€108.53m

0.1x

P/S Ratio

-0.7x

P/E Ratio

Is CDG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CDG income statement (TTM)
Revenue	US$116.91m
Cost of Revenue	US$27.38m
Gross Profit	US$89.53m
Other Expenses	US$110.45m
Earnings	-US$20.92m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-16.84
Gross Margin	76.58%
Net Profit Margin	-17.89%
Debt/Equity Ratio	259.6%

How did CDG perform over the long term?

See historical performance and comparison

This company listing is no longer active

CDG Stock Overview

Rewards

Risk Analysis

Acorda Therapeutics, Inc. Competitors

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:PA8

€2.6m

XTRA:HPHA

€103.9m

Price History & Performance

Recent News & Updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40